Literature DB >> 12921944

Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study.

Athena M Cherry1, Stephanie R Brockman, Sarah F Paternoster, Gary A Hicks, Donna Neuberg, Rodney R Higgins, John M Bennett, Peter L Greenberg, Kenneth Miller, Martin S Tallman, Jacob Rowe, Gordon W Dewald.   

Abstract

Cytogenetic analysis can be important in determining the prognosis and diagnosis of a number of hematological disorders, including myelodysplastic syndromes (MDS). Here, we compared metaphase chromosomal analyses on bone marrow aspirates from MDS patients with interphase fluorescence in situ hybridization (FISH) using probes specific for chromosomes nos. 5, 7, 8, 11, 13 and 20. Forty-three patients enrolled in ECOG protocol E1996 for low risk MDS and five patients enrolled in ECOG protocol E3996 for high risk MDS were studied by both metaphase chromosomal analysis and interphase FISH. Excluding those with a clonal loss of the Y chromosome, an abnormal clone was detected by cytogenetic analysis in 18 of 48 samples (37.5%). In comparison, our FISH panel detected an abnormal clone in 17 of 48 samples (35.4%). Twenty-nine of 30 samples with apparently normal karyotypes, including those with a missing Y chromosome, were also normal by our FISH panel. One patient had an occult deletion of chromosome 11 that was detected by FISH. These results indicate that around 60% of patients with MDS do not have abnormalities that are detectable by either chromosomal or FISH studies. In addition, it appears that interphase FISH studies are nearly as sensitive as cytogenetic analyses and can be a useful tool in studying bone marrow aspirates where cytogenetic analysis is not possible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12921944     DOI: 10.1016/s0145-2126(03)00104-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

Review 1.  Myelodysplastic syndromes.

Authors:  Olatoyosi Odenike; John Anastasi; Michelle M Le Beau
Journal:  Clin Lab Med       Date:  2011-10-10       Impact factor: 1.935

2.  Interphase Chromosome Flow-FISH.

Authors:  Keyvan Keyvanfar; Jason Weed; Prashanth Swamy; Sachiko Kajigaya; Rodrigo T Calado; Neal S Young
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

3.  Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.

Authors:  Gudrun Göhring; Aristoteles Giagounidis; Guntram Büsche; Winfried Hofmann; Hans Heinrich Kreipe; Pierre Fenaux; Eva Hellström-Lindberg; Brigitte Schlegelberger
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

4.  Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach.

Authors:  Won Kyung Kwon; Jin Young Lee; Yeung Chul Mun; Chu Myong Seong; Wha Soon Chung; Jungwon Huh
Journal:  Korean J Hematol       Date:  2010-09-30

5.  Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.

Authors:  Sara A Monaghan; Lijun Dai; Markus Y Mapara; Daniel P Normolle; Susanne M Gollin; Suzanne Lentzsch
Journal:  Leuk Lymphoma       Date:  2013-01-28

6.  Myelodysplastic syndrome in elderly patients: correlation of CBC with cytogenetic and FISH analysis.

Authors:  K-E T Codispoti; L Depalma
Journal:  Int J Lab Hematol       Date:  2009-12-23       Impact factor: 2.877

7.  Evaluation of the utility of peripheral blood vs bone marrow in karyotype and fluorescence in situ hybridization for myelodysplastic syndrome diagnosis.

Authors:  Zhaleh Asadi Fakhr; Valiollah Mehrzad; Amin Izaditabar; Mansoor Salehi
Journal:  J Clin Lab Anal       Date:  2018-06-11       Impact factor: 2.352

8.  Comparison of Diagnostic Yield of a FISH Panel Against Conventional Cytogenetic Studies for Hematological Malignancies: A South Indian Referral Laboratory Analysis Of 201 Cases

Authors:  Vishal Ashok; Ramya Ranganathan; Smitha Chander; Sharat Damodar; Sunil Bhat; Nataraj K S; Satish Kumar A; Sachin Suresh Jadav; Mahesh Rajashekaraiah; Sundareshan T S
Journal:  Asian Pac J Cancer Prev       Date:  2017-12-29

9.  Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.

Authors:  Silvia Maria Meira Magalhães; Lígia Niero-Melo; Maria de Lourdes Lopes Ferrari Chauffaille; Elvira Deolinda Rodrigues Pereira Velloso; Irene Lorand-Metze; Renata Buzzini; Wanderley Marques Bernardo
Journal:  Hematol Transfus Cell Ther       Date:  2018-07-02

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.